Phase 2 Readout
AIM: Phase 2 Readout: ampligen
December 31, 2026 · ampligen. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 31, 2026
- Company
- AIM ImmunoTech Inc. (AIM)
- Drug
- ampligen
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Readout~quarter
Phase 2 Readout: ampligen
- Company
- AIM ImmunoTech Inc. (AIM)
- Drug
- ampligen
- Indication
- pancreatic cancer